Kyoto University

Mie University

Kabushiki Kaisha Yakult Honsha

General Incorporated Association Pharma Valley Project Supporting Organization

United Immunity, Co., Ltd.

Immunofrontier, Inc.

Naozumi Harada

Hiroshi Shiku

Kazunari Akiyoshi

Daisuke Muraoka

Akira Asai

Naohisa Ogo

Naohiro Seo

Masahiro Urushihara

Shin-ichi Sawada

Fumiyasu Momose

Kenji Nagura

An object is to provide a technique of forming CpG oligonucleotides and hydrophobized polysaccharides into complexes. This object is achieved by a complex comprising a modified CpG oligonucleotide containing a hydrophobic group A having a sterol skeleton, and a modified polysaccharide containing a hydrophobic group B.

Complex

To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.

Agent for overcoming immunosuppression and use thereof

A long-chain peptide antigen includes a plurality of epitopes. An interepitope sequence located between two of the plurality of epitopes contains four to ten consecutive tyrosines. The long-chain peptide antigen may be administered to a patient together with a hydrophobized polysaccharide, such as cholesterol-modified pullulan, and/or an adjuvant, such as CpG oligo DNA.

Long chain antigen containing interepitope sequence that promotes antigen presentation to T cells

Therapeutic agents effective for treating cell-proliferative diseases contain extracellular vesicles (exosomes) released from cytotoxic T cells or miRNA obtained from extracellular vesicles (exosomes) released from cytotoxic T cells, such as human CD8+ T cells. Such therapeutic agents suppress the proliferation of mesenchymal cells surrounding cancer cells, e.g., by killing the mesenchymal cells, such that the cancer cells become isolated and unable to metastasize. Cell-proliferative diseases are thus treatable by administering such a therapeutic agent to a patient.

Therapeutic agent associated with suppression of proliferation and metastasis of tumor, which comprises exosomes released from cytotoxic T cells and targets cancer stromal/mesenchymal cells

Growing community of inventors

Tsu, Japan

Naozumi Harada